Merck & Company Inc (MRK)vsPhreesia Inc (PHR)
MRK
Merck & Company Inc
$146.99
-0.16%
HEALTHCARE · Cap: $368.89B
PHR
Phreesia Inc
$12.62
-1.48%
HEALTHCARE · Cap: $795.13M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 13169% more annual revenue ($67.38B vs $507.79M). MRK leads profitability with a 3.6% profit margin vs 2.1%. PHR trades at a lower P/E of 75.3x. PHR earns a higher WallStSmart Score of 49/100 (D+).
MRK
Hold44
out of 100
Grade: D
PHR
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-72.9%
Fair Value
$84.87
Current Price
$146.99
$62.12 premium
Margin of Safety
+71.1%
Fair Value
$43.30
Current Price
$12.62
$30.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 5.5B in free cash flow
Earnings expanding 200.0% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Trading at 8.7x book value
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Smaller company, higher risk/reward
ROE of 2.8% — below average capital efficiency
2.1% margin — thin
Operating margin of 4.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PHR
The strongest argument for PHR centers on EPS Growth, Debt/Equity, Price/Book. Revenue growth of 10.4% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : PHR
The primary concerns for PHR are Market Cap, Return on Equity, Profit Margin. A P/E of 75.3x leaves little room for execution misses. Thin 2.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
PHR carries more volatility with a beta of 0.72 — expect wider price swings.
PHR is growing revenue faster at 10.4% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PHR scores higher overall (49/100 vs 44/100) and 10.4% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Phreesia Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Phreesia, Inc. provides integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company is headquartered in Raleigh, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?